A small subgroup analysis of two randomized trials found that median time to resolution of diabetic ketoacidosis was 13 hours in patients who received balanced crystalloids versus nearly 17 hours in those who received saline.
In a recent study, a serum C-peptide testing program resulted in reclassification of the cause of diabetes in about 7% of the cohort tested at one diabetes center in Scotland. Reclassification was most likely in those diagnosed at age 30 years or
The advent of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists could reduce cardiovascular adverse events and progression to end-stage kidney disease, the American Heart Association (AHA) scientific statement
The authors of the retrospective study called for additional research on the pathogenesis of acute kidney injury (AKI) and the associated risk factors, such as medications, in diabetic patients.
Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.
An international expert group convened by the American Diabetes Association proposed that the criterion for diabetes remission be an HbA1c level below 6.5%, measured at least three months after glucose-lowering drugs are stopped.
A pooled analysis of three randomized clinical trials found reductions in major adverse cardiac or cerebrovascular events after percutaneous coronary intervention (PCI) at 3.9-year follow-up only in patients with low-density lipoprotein (LDL)
In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with
A meta-analysis of six studies found that patient-led titration was associated with lower HbA1c and fasting plasma glucose levels than physician-led titration, although hypoglycemia risk and body weight were slightly higher.
Patients with type 2 diabetes who had no diabetes-related polyneuropathy, diabetes-related polyneuropathy with pain, and diabetes-related polyneuropathy without pain were compared in an industry-funded retrospective study.